Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010)

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010)

【24h】

Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010)

机译：Plasmamatch试验治疗队的结果：II型鼻替尼患者在ER正乳腺癌或漂亮乳腺癌中的氟氯雌肽中的II期试验，通过CTDNA筛选鉴定的HER阴性乳腺癌（CRUK / 15/010）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Plasmamatch试验治疗队的结果：II型鼻替尼患者在ER正乳腺癌或漂亮乳腺癌中的氟氯雌肽中的II期试验，通过CTDNA筛选鉴定的HER阴性乳腺癌（CRUK / 15/010）
3. Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：PlasmAmatch试验队列的结果：通过CTDNA筛选鉴定的ESR1突变患者延长剂量氟斯特的II期试验（CRUK / 15/010）
4. Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Plasmamatch试验队列的结果：通过CTDNA检测或肿瘤测序鉴定的AKT激活篮突变患者Capivasertib的II期试验（CRUK / 15/010）
5. A Single Tube Screening of Endocrine Therapy Resistance ESR1 Mutations in ER-Positive Breast Cancer [C] . Akihiro Tsuyada, Shunsuke Nakano, Toshimitsu Ichijo, International Molecular Medicine Tri-Conference. . 2016

机译：ER阳性乳腺癌内分泌治疗抗ESR1突变的单管筛选
6. Molecular aspects of targeting estrogen receptor (ER)-positive and ER-negative breast cancer cells. [D] . Venkiteswaran, Sripriya. 2006

机译：靶向雌激素受体（ER）阳性和ER阴性乳腺癌细胞的分子方面。
7. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial [O] . Joanne Mortimer, Jack Di Palma, Kendra Schmid, 2019

机译：奈拉替尼相关腹泻在HER2阳性乳腺癌患者中的发生和影响模式：来自ExtriNET III期随机试验的分析
8. Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer [O] . L.M. Smyth, C. Saura, S.A. Piha-Paul, 2019

机译：II期首脑会议试验的更新：Neratinib + Her2-突变体，HR阳性，转移性乳腺癌的氟

Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010)

著录项

相似文献

相关主题

期刊订阅